---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-126728"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2025-12-31T23:59:59+00:00"
generated_at: "2026-05-16T11:56:59.736960+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Emmaus Life Sciences licenses Endari to NeoImmuneTech for US/Canada with upfront and royalties

## Summary
- Emmaus grants NeoImmuneTech (NIT) exclusive rights to market Endari for sickle cell disease in US and Canada; upfront payment plus royalty on NIT sales.
- Effective date conditioned on NIT obtaining regulatory approvals; either party may terminate if not met by Oct 1, 2026.
- Emmaus will supply Endari to NIT at cost-plus margin; selected US sales force to transfer to NIT pending effective date.
- If NIT fails to meet annual minimum sales, the license becomes non-exclusive.
- Emmaus CEO says deal allows refocus on higher-growth regions: Middle East, Brazil, Europe.

## SEC filing metadata
- accession: 0001213900-25-126728
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2025-12-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390025126728/0001213900-25-126728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390025126728/ea027134801-8k_emmauslife.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-126728
- JSON: https://secwatch.observer/filing/0001213900-25-126728.json
- Plain text: https://secwatch.observer/filing/0001213900-25-126728.txt

## Key facts
- Material Agreements
  Emmaus Life Sciences, Inc. entered into License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. valued at an upfront payment (effective 2025-12-24).
  - Action: entry
  - Agreement: license
  - Counterparty: NeoImmuneTech, Inc.
  - Value: an upfront payment
  - Effective: 2025-12-24
  source text: On December 24, 2025, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” and the “company”) and NeoImmuneTech, Inc. (KOSDAQ: 950220.KQ), or NIT, entered into a License and Exclusive Distribution Agreement, or License Agreement, dated as of the same day pursuant to which we granted NIT an exclusive (including as to Emmaus) license to all our rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents, or the Products, in sickle cell disease, or the Field, in the U.S. and its territories and possession and Canada, referred to as the Territory, in exchange for an upfront payment and a royalty on NIT’s Product sales.
  evidence_url: https://www.sec.gov/Archives/edgar/data/822370/000121390025126728/0001213900-25-126728-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.